Immunological background for treatments with biologicals in CRSwNP
Open Access
- 8 April 2021
- journal article
- Published by Heighten Science Publications Corporation in Archives of Asthma, Allergy and Immunology
- Vol. 5 (1), 022-029
- https://doi.org/10.29328/journal.aaai.1001026
Abstract
Background: Chronic rhinosinusitis (CRS) is a heterogeneous and multifactorial inflammatory disease of the nasal and paranasal mucosa. To date, no internationally standardized uniform classification has been developed for this disease. Usually, a phenotype classification according to CRS with (CRSwNP) and without (CRSsNP) polyposis is performed. However, through a variety of studies, it has been shown that even within these phenotypes, different endotypes of CRS exist, each with a different underlying inflammatory pathophysiology. In this mini-review, we aim to outline the essential immunological processes in CRSwNP and to highlight the modern therapeutic options with biologics derived from this disease. Methods: Current knowledge on the immunological and molecular processes of CRS, especially CRSwNP, was compiled by means of a structured literature review. Medline, PubMed, national/international trial and guideline registries as well as the Cochrane Library were all searched. Results: Based on the current literature, the different immunological processes involved in CRS and nasal polyps were elaborated. Current studies on the therapy of eosinophilic diseases such as asthma and polyposis are presented and their results discussed. Conclusion: Understanding the immunological basis of CRSwNP may help to develop new personalized therapeutic approaches using biologics. Currently, 2 biologics (dupilumab, omalizumab) have been approved for the therapy of CRSwNP (polyposis nasi) in Europe.Keywords
This publication has 100 references indexed in Scilit:
- Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunityJournal of Allergy and Clinical Immunology, 2012
- Increased expression of CC chemokine ligand 18 in patients with chronic rhinosinusitis with nasal polypsJournal of Allergy and Clinical Immunology, 2012
- IL-33 enhances Siglec-8 mediated apoptosis of human eosinophilsCytokine, 2012
- Increased expression of the chemokine CCL23 in eosinophilic chronic rhinosinusitis with nasal polypsJournal of Allergy and Clinical Immunology, 2011
- Characterization of the Cysteinyl Leukotriene 2 Receptor in Novel Expression Sites of the Gastrointestinal TractThe American Journal of Pathology, 2011
- TH2 heterogeneity: Does function follow form?Journal of Allergy and Clinical Immunology, 2010
- Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polypsJournal of Allergy and Clinical Immunology, 2010
- A novel IL-1 family cytokine, IL-33, potently activates human eosinophilsJournal of Allergy and Clinical Immunology, 2008
- Evidence of a role for B cell–activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polypsJournal of Allergy and Clinical Immunology, 2008
- Disruption of the murine IL-4 gene blocks Th2 cytokine responsesNature, 1993